Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusuke Kuwahara

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cancer Research Communications|December 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric CancerShigehiro Koganemaru, Shohei Koyama, Fumitaka Suto, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Journal of Human Genetics|April 10, 2015
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studiesShigeo Kamitsuji, Takashi Matsuda, Koichi Nishimura, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cancer Research Communications|December 16, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric CancerShigehiro Koganemaru, Shohei Koyama, Fumitaka Suto, et al.
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Nature Medicine|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trialKohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
Journal of Human Genetics|April 10, 2015
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studiesShigeo Kamitsuji, Takashi Matsuda, Koichi Nishimura, et al.
Pageof 4